Abivax SA Unveils New Ulcerative Colitis Treatment Data

Abivax SA Sponsored ADR (ABVX) has released an update.

Abivax SA announced they will present three new scientific abstracts on their lead drug candidate, obefazimod, during the UEG Week 2024 in Vienna, Austria. The data includes Phase 2b trial results for obefazimod’s efficacy and safety in treating ulcerative colitis (UC), highlighting its potential as a once-daily oral therapy. The company’s commitment to advancing UC treatment is supported by positive clinical trial outcomes and the initiation of a Phase 3 clinical trial program.

For further insights into ABVX stock, check out TipRanks’ Stock Analysis page.